Outsourcing

Chris Spivey is the editorial director of 

Videos

Frontage Laboratories' Marianna Tcherpakov, PhD, director of Business Development, CMC Services, discussed the CDMO’s role in enabling startup biotechs solve complex technical challenges for scale up.

A Look at CDMO–Biotech Partnerships and Tackling Complex Technical Challenges (BIO 2024)

Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT. 

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Buy, Sell, Hold: Cell and Gene Therapy - Part 2

Buy, Sell, Hold: Cell and Gene Therapy - Part 3

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Thermo Fisher Scientific's launch of its Accelerator Drug Development follows expansions of sites in Cincinnati, Ohio, and Bend, Ore., earlier in 2024 to enable R&D, manufacturing, and testing.

Thermo Fisher Introduces New CDMO and CRO Services at CPHI Milan 2024

Feliza Mirasol is the science editor for 

Results from the CPHI annual survey show that 49% of industry respondents are “highly positive” on the contract services sector seeing growth over the next 18 months.

CPHI Milan Survey Predicts Faster CDMO Growth in 2025 While Finding No Industry Favor for BIOSECURE Act

The two companies are partnering to provide logistics and manufacturing services to biotechnology and pharma companies.

SK pharmteco and Cryoport Collaborate on Cell and Gene Therapies

Contract organizations offer sponsors specialized equipment, capacity, and expertise for testing, manufacturing, and packaging bio/pharmaceutical products.

Contracting Out Frees Sponsors Up

Editor of Pharmaceutical Technology Europe

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services. 

Agilent Expands Biopharma Offerings with BIOVECTRA Acquisition

The company plans to invest approximately €900 million (US$983 million) to expand its peptide platform at its Colorado, US, site and in Europe.

Contract Manufacturing, General